Systematic review and meta-analysis finds 4% to 13% cirrhosis prevalence in individuals with hepatitis B, highlighting urgent need for antiviral therapy.
Depending on the setting, between 4% and 13% of HBV-infected individuals in SSA have cirrhosis and need immediate antiviral therapy. These estimates should be considered when planning HBV treatment strategies and resource allocation.
No takes yet. Share an insight, caveat, or question.
Surial et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: